NZ596215A - Extended release formulations of erythromycin derivatives - Google Patents

Extended release formulations of erythromycin derivatives

Info

Publication number
NZ596215A
NZ596215A NZ596215A NZ59621598A NZ596215A NZ 596215 A NZ596215 A NZ 596215A NZ 596215 A NZ596215 A NZ 596215A NZ 59621598 A NZ59621598 A NZ 59621598A NZ 596215 A NZ596215 A NZ 596215A
Authority
NZ
New Zealand
Prior art keywords
clarithromycin
extended release
composition
release formulations
erythromycin derivatives
Prior art date
Application number
NZ596215A
Inventor
Sheri L Crampton
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25278344&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ596215(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of NZ596215A publication Critical patent/NZ596215A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)

Abstract

596215 EXTENDED RELEASE FORMULATIONS OF ERYTHROMYCIN DERIVATIVES Provided is a pharmaceutical composition for extended release of clarithromycin in the gastrointestinal environment, comprising 50% by weight clarithromycin and from 10 to 30% by weight of hydroxypropylmethyl cellulose having a viscosity of 100 cps, so that when ingested orally, the composition induces statistically significantly lower mean fluctuation index in the plasma than an immediate release composition of clarithromycin while maintaining bioavailability substantially equivalent to that of the immediate release composition of clarithromycin, preparable by dry blending the polymer, clarithromycin, and other excipients followed by granulating the mixture using water until proper granulation is obtained.
NZ596215A 1997-04-11 1998-03-06 Extended release formulations of erythromycin derivatives NZ596215A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/838,900 US6010718A (en) 1997-04-11 1997-04-11 Extended release formulations of erythromycin derivatives

Publications (1)

Publication Number Publication Date
NZ596215A true NZ596215A (en) 2013-09-27

Family

ID=25278344

Family Applications (3)

Application Number Title Priority Date Filing Date
NZ537410A NZ537410A (en) 1997-04-11 1998-03-06 Extended release formulations of clarithromycin that minimise adverse effects and provide at least equivalent to tablet or liquid formulations
NZ596215A NZ596215A (en) 1997-04-11 1998-03-06 Extended release formulations of erythromycin derivatives
NZ337120A NZ337120A (en) 1997-04-11 1998-03-06 Sustained release formulations of an erythromycin derivative and a pharmaceutically acceptable water -soluble polymer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NZ537410A NZ537410A (en) 1997-04-11 1998-03-06 Extended release formulations of clarithromycin that minimise adverse effects and provide at least equivalent to tablet or liquid formulations

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ337120A NZ337120A (en) 1997-04-11 1998-03-06 Sustained release formulations of an erythromycin derivative and a pharmaceutically acceptable water -soluble polymer

Country Status (29)

Country Link
US (1) US6010718A (en)
EP (2) EP0973527B1 (en)
JP (2) JP4394754B2 (en)
KR (1) KR100484559B1 (en)
CN (1) CN100408044C (en)
AR (1) AR012358A1 (en)
AT (1) ATE253371T1 (en)
AU (1) AU737324B2 (en)
BG (1) BG65188B1 (en)
BR (1) BR9807974A (en)
CA (1) CA2285266C (en)
CO (1) CO4940403A1 (en)
CZ (1) CZ294333B6 (en)
DE (1) DE69819481T2 (en)
DK (1) DK0973527T3 (en)
ES (1) ES2205454T3 (en)
HK (1) HK1027023A1 (en)
HU (1) HUP0001382A3 (en)
IL (3) IL131616A0 (en)
NO (1) NO994946D0 (en)
NZ (3) NZ537410A (en)
PL (2) PL336142A1 (en)
PT (1) PT973527E (en)
SA (1) SA98190065B1 (en)
SK (2) SK288109B6 (en)
TR (2) TR199902149T2 (en)
TW (1) TW576743B (en)
WO (1) WO1998046239A1 (en)
ZA (1) ZA982916B (en)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6551616B1 (en) * 1997-04-11 2003-04-22 Abbott Laboratories Extended release formulations of erythromycin derivatives
AU773863B2 (en) * 1997-04-11 2004-06-10 Bgp Products Operations Gmbh Extended release formulations of erythromycin derivatives
US6099859A (en) 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
TR200000054A2 (en) * 2000-01-05 2001-08-21 Sanovel İlaç San. Ve Ti̇c. Anoni̇m Şi̇rketi̇ Sustained-release tablet formulations containing clarithromycin.
US6565882B2 (en) * 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6544555B2 (en) * 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
PL366021A1 (en) * 2000-02-29 2005-01-24 Teva Pharmaceutical Industries Ltd. Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same
DE60138876D1 (en) * 2000-03-28 2009-07-16 Sandoz Ag TASTE-MASKED GRANULATED PARTICLES
IN192748B (en) * 2000-08-29 2004-05-15 Ranbaxy Lab Ltd
US20020068078A1 (en) * 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US6541014B2 (en) * 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
WO2002038577A2 (en) * 2000-10-13 2002-05-16 Advancis Pharmaceuticals Extended release erythromycin derivatives
US6790459B1 (en) 2000-11-03 2004-09-14 Andrx Labs, Llc Methods for treating diabetes via administration of controlled release metformin
US20060034922A1 (en) * 2000-11-03 2006-02-16 Andrx Labs, Llc Controlled release metformin compositions
US6866866B1 (en) * 2000-11-03 2005-03-15 Andrx Labs, Llc Controlled release metformin compositions
US20020197314A1 (en) * 2001-02-23 2002-12-26 Rudnic Edward M. Anti-fungal composition
CA2458776A1 (en) * 2001-08-29 2003-03-06 Ashok Rampal Controlled release formulation of clarithromycin or tinidazol
US6673369B2 (en) 2001-08-29 2004-01-06 Ranbaxy Laboratories Limited Controlled release formulation
US20050249786A1 (en) * 2001-09-28 2005-11-10 Solubest Ltd. Hydrophilic dispersions of nanoparticles of inclusion complexes of amorphous compounds
US20050233003A1 (en) * 2001-09-28 2005-10-20 Solubest Ltd. Hydrophilic dispersions of nanoparticles of inclusion complexes of salicylic acid
US6878693B2 (en) * 2001-09-28 2005-04-12 Solubest Ltd. Hydrophilic complexes of lipophilic materials and an apparatus and method for their production
US20050191359A1 (en) * 2001-09-28 2005-09-01 Solubest Ltd. Water soluble nanoparticles and method for their production
US20050227911A1 (en) * 2001-09-28 2005-10-13 Solubest Ltd. Hydrophilic dispersions of nanoparticles of inclusion complexes of macromolecules
EP1443910A1 (en) * 2001-11-02 2004-08-11 Wockhardt Limited Controlled release compositions for macrolide antimicrobial agents
US7700851B2 (en) * 2001-11-13 2010-04-20 U.S. Smokeless Tobacco Company Tobacco nicotine demethylase genomic clone and uses thereof
US20030203055A1 (en) * 2002-03-15 2003-10-30 Cypress Bioscience, Inc. Methods of treating visceral pain syndromes
WO2003099214A2 (en) * 2002-05-23 2003-12-04 Andrx Corporation Biguanide formulations
WO2003105810A1 (en) * 2002-06-14 2003-12-24 Andrx Corporation Pharmaceutical compositions for drugs having ph-dependentsolubility
US20060003004A1 (en) * 2002-10-25 2006-01-05 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
US20040132826A1 (en) * 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
US20040131662A1 (en) 2003-11-12 2004-07-08 Davidson Robert S. Method and apparatus for minimizing heat, moisture, and shear damage to medicants and other compositions during incorporation of same with edible films
US9561182B2 (en) * 2003-08-22 2017-02-07 Cure Pharmaceutical Corporation Edible films for administration of medicaments to animals, methods for their manufacture and methods for their use for the treatment of animals
US8999372B2 (en) * 2002-11-14 2015-04-07 Cure Pharmaceutical Corporation Methods for modulating dissolution, bioavailability, bioequivalence and drug delivery profile of thin film drug delivery systems, controlled-release thin film dosage formats, and methods for their manufacture and use
US20040191302A1 (en) 2003-03-28 2004-09-30 Davidson Robert S. Method and apparatus for minimizing heat, moisture, and shear damage to medicants and other compositions during incorporation of same with edible films
WO2004067039A1 (en) * 2003-01-28 2004-08-12 Collegium Pharmaceutical, Inc. Multiparticulate compositions of milnacipran for oral administration
US20040185097A1 (en) * 2003-01-31 2004-09-23 Glenmark Pharmaceuticals Ltd. Controlled release modifying complex and pharmaceutical compositions thereof
BRPI0410098A (en) * 2003-05-06 2006-05-16 Nirmal Mulye controlled release formulation of erythromycin derivatives
US7063862B2 (en) * 2003-06-03 2006-06-20 Biokey, Inc. Pharmaceutical composition and method for treating
CA2673334C (en) * 2003-06-16 2013-11-12 Andrx Pharmaceuticals, Llc Oral extended-release composition
US20050053658A1 (en) * 2003-09-09 2005-03-10 Venkatesh Gopi M. Extended release systems for macrolide antibiotics
WO2005009368A2 (en) * 2003-07-21 2005-02-03 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
WO2005009364A2 (en) * 2003-07-21 2005-02-03 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
WO2005009365A2 (en) * 2003-07-21 2005-02-03 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
WO2005016311A1 (en) * 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Robust pellet
AU2004264356B2 (en) 2003-08-12 2011-01-27 Shionogi, Inc. Antibiotic product, use and formulation thereof
WO2005023184A2 (en) * 2003-08-29 2005-03-17 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
WO2005023221A1 (en) * 2003-09-05 2005-03-17 Ranbaxy Laboratories Limited Clarithromycin formulations having improved biovailability
WO2005027877A1 (en) * 2003-09-15 2005-03-31 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
US20050084540A1 (en) * 2003-10-17 2005-04-21 Indranil Nandi Taste masking antibiotic composition
US8168228B2 (en) * 2003-10-17 2012-05-01 Sandoz Ag Antibiotic clarithromycin micropellet compositions
CN1874767A (en) 2003-10-29 2006-12-06 惠氏公司 Sustained release pharmaceutical compositions comprising APLINDORE and derivatives thereof
US20050101547A1 (en) * 2003-11-06 2005-05-12 Sadatrezaei Mohsen Stabilized azithromycin composition
BRPI0417348A (en) * 2003-12-04 2007-03-13 Pfizer Prod Inc spray gelatinization process using an extruder for preparing multiparticulate crystalline drug compositions preferably containing a poloxamer and a glyceride
AU2004294813A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Spray-congeal process using an extruder for preparing multiparticulate azithromycin compositions containing preferably a poloxamer and a glyceride
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
BRPI0416534A (en) * 2003-12-04 2007-01-09 Pfizer Prod Inc multiparticulate compositions with improved stability
RU2006119453A (en) * 2003-12-04 2007-12-20 Пфайзер Продактс Инк. (Us) PRODUCTION OF MEDICINES ASITROMYCIN WITH A LARGE NUMBER OF PARTICLES BASED ON THE APPLICATION OF LIQUIDS OF METHODS
ATE399536T1 (en) * 2003-12-04 2008-07-15 Pfizer Prod Inc METHOD FOR PRODUCING PHARMACEUTICAL MULTIPARTICLE PRODUCTS
WO2005053652A1 (en) 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
WO2005053639A2 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Controlled release multiparticulates formed with dissolution enhancers
US7943585B2 (en) 2003-12-22 2011-05-17 Sandoz, Inc. Extended release antibiotic composition
US20050142187A1 (en) * 2003-12-24 2005-06-30 Treacy Donald J.Jr. Enhanced absorption of modified release dosage forms
EP1732518A1 (en) * 2004-03-24 2006-12-20 Lupin Ltd. Clarithromycin extended release formulation
US20050260263A1 (en) * 2004-05-18 2005-11-24 Panion & Bf Biotech Inc. Sustained release formulation for sparingly soluble main drugs
KR101122096B1 (en) * 2004-05-20 2012-03-15 주식회사종근당 Pharmaceutical composition of clarithromycin and its manufacturing method for taste masking and increasing dissolution rate
KR100621342B1 (en) * 2004-06-22 2006-09-18 (주)다산메디켐 A clarithromycin-containing pharmaceutical composition and a process for preparing the same
WO2006014427A1 (en) * 2004-07-02 2006-02-09 Advancis Pharmaceutical Corporation Tablet for pulsed delivery
US8778924B2 (en) * 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
WO2007126039A1 (en) * 2006-04-28 2007-11-08 Shionogi & Co., Ltd. Coated macrolide antibiotic preparation
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
WO2007143507A2 (en) * 2006-06-05 2007-12-13 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted erythromycin analogs
EP2283824B1 (en) 2009-07-30 2017-04-19 Special Products Line S.p.A. Compositions and formulations based on swellable matrices for sustained release of poorly soluble drugs such as clarithromycin
EP2671571A1 (en) 2012-06-05 2013-12-11 Sanovel Ilac Sanayi ve Ticaret A.S. Controlled-release formulations of clarithromycin

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3870790A (en) * 1970-01-22 1975-03-11 Forest Laboratories Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose
US4226849A (en) * 1979-06-14 1980-10-07 Forest Laboratories Inc. Sustained release therapeutic compositions
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
DE3583799D1 (en) * 1985-01-11 1991-09-19 Abbott Lab Ltd SOLID PREPARATION WITH SLOW RELEASE.
FR2585948B1 (en) * 1985-08-06 1988-12-16 Pf Medicament PROCESS FOR THE MANUFACTURE OF INDOMETACIN TABLETS
US4808411A (en) * 1987-06-05 1989-02-28 Abbott Laboratories Antibiotic-polymer compositions
US4925675A (en) 1988-08-19 1990-05-15 Himedics, Inc. Erythromycin microencapsulated granules
JP3265680B2 (en) * 1992-03-12 2002-03-11 大正製薬株式会社 Oral pharmaceutical composition
US5393765A (en) * 1993-12-13 1995-02-28 Hoffmann-La Roche Inc. Pharmaceutical compositions with constant erosion volume for zero order controlled release
CN1096862C (en) * 1994-05-06 2002-12-25 辉瑞大药厂 Controlled-release dosage forms of azithromycin
JPH0995440A (en) * 1995-09-29 1997-04-08 Roussel Morishita Kk Sustained release preparation and its production
US5919489A (en) * 1995-11-01 1999-07-06 Abbott Laboratories Process for aqueous granulation of clarithromycin
US5705190A (en) * 1995-12-19 1998-01-06 Abbott Laboratories Controlled release formulation for poorly soluble basic drugs
US5972389A (en) * 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter

Also Published As

Publication number Publication date
SK288109B6 (en) 2013-08-02
CA2285266A1 (en) 1998-10-22
NO994946L (en) 1999-10-11
CZ294333B6 (en) 2004-12-15
NO994946D0 (en) 1999-10-11
SK138099A3 (en) 2000-04-10
BG103862A (en) 2000-07-31
NZ337120A (en) 2001-04-27
DE69819481T2 (en) 2004-08-26
TW576743B (en) 2004-02-21
ES2205454T3 (en) 2004-05-01
DK0973527T3 (en) 2003-11-24
JP2009137988A (en) 2009-06-25
EP0973527B1 (en) 2003-11-05
NZ537410A (en) 2007-06-29
WO1998046239A1 (en) 1998-10-22
IL131616A (en) 2013-03-24
JP2001524955A (en) 2001-12-04
SA98190065B1 (en) 2006-06-17
PL336142A1 (en) 2000-06-05
AR012358A1 (en) 2000-10-18
EP1340495A1 (en) 2003-09-03
EP0973527A1 (en) 2000-01-26
KR20010006251A (en) 2001-01-26
HUP0001382A2 (en) 2000-09-28
TR200707263T2 (en) 2008-01-21
CN1494911A (en) 2004-05-12
AU737324B2 (en) 2001-08-16
HUP0001382A3 (en) 2001-08-28
IL223035A0 (en) 2012-12-31
CA2285266C (en) 2001-07-24
CO4940403A1 (en) 2000-07-24
HK1027023A1 (en) 2001-01-05
ZA982916B (en) 1998-10-09
KR100484559B1 (en) 2005-04-22
DE69819481D1 (en) 2003-12-11
CN100408044C (en) 2008-08-06
TR199902149T2 (en) 1999-12-21
BG65188B1 (en) 2007-06-29
CZ347199A3 (en) 2000-01-12
JP4394754B2 (en) 2010-01-06
AU6346398A (en) 1998-11-11
JP5188994B2 (en) 2013-04-24
PT973527E (en) 2004-01-30
BR9807974A (en) 2000-03-08
SK288127B6 (en) 2013-10-02
ATE253371T1 (en) 2003-11-15
EP1340495B1 (en) 2016-08-10
US6010718A (en) 2000-01-04
IL131616A0 (en) 2001-01-28
PL402949A1 (en) 2013-04-15

Similar Documents

Publication Publication Date Title
NZ596215A (en) Extended release formulations of erythromycin derivatives
CA2102630A1 (en) Pharmaceutical compositions of compacted medicaments
KR950007841A (en) Sustained-release drug formulations containing tramadol salts
EP1586314A1 (en) Nateglinide tablet composition
SE8207167D0 (en) METHOD OF PREPARING THERAPEUTIC COMPOUNDS WITH EXTENDED DELIVERY TIME BASED ON HYDROXYPROPYLMETHYL CELLULOSA
SE8301579L (en) METHOD FOR PREPARING THERAPEUTIC COMPOUNDS WITH WINDOW-MAINTENANCE LOSS, BASED ON HYDROXYPROPYLMETHYL CELLULOSA WITH HIGH MOLECULE WEIGHT
BR0010485A (en) Formulations of erythromycin derivatives of prolonged release
CA2232152A1 (en) Bioadhesive solid dosage form
KR890004686A (en) Sustained release Etodolac
HU900638D0 (en) Process for preparing modified gembifrozil preparations with retard release
NZ510563A (en) Multiple unit controlled food effect-independent release pharmaceutical preparations and method for preparing the same
CZ2001792A3 (en) Pharmaceutical composition comprising entacapone or nitecapone as well as a cross-linked cellulose derivative
GB2176704A (en) Solid, stable dosage forms with an elastic film coating
KR850700212A (en) Sustained Release Pharmaceutical Wexel
HRP20040384A2 (en) Process for preparing quick dissolving high loading ribavirin compositions
KR100522239B1 (en) Compositions for controlled release acetaminophen dosage forms
WO2017116152A1 (en) Mucoadhesive pharmaceutical composition and preparation method therefor
AU6430198A (en) New formulation
CA2055905A1 (en) Pharmaceutical composition comprising calcium polycarbophil
CA2106216A1 (en) Chewable antacid compositions
IL123185A0 (en) Stable solid formulation of enalapril salt and process for preparation thereof
CA2435714A1 (en) Fenofibrate tablets
HK1043945B (en) Pharmaceutical capsule compositions containing loratadine and pseudoephedrine
KR960028916A (en) A flavanol lignan preparation having excellent release and absorption ability
CA2361496A1 (en) Ph independent extended release pharmaceutical formulation

Legal Events

Date Code Title Description
ERR Error or correction

Free format text: THE FILED DATE HAS BEEN CORRECTED TO 06/03/1998; THE PATENT COMPLETE SPECIFICATION DATE HAS BEEN CORRECTED TO 06/03/1998

Effective date: 20130815

ERR Error or correction

Free format text: THE MISSING INVENTOR HAS BEEN ADDED (1345898, AL_RAZZAK, LAMAN A.; 1345899, CRAMPTON, SHERI L.; 1345900, GUSTAVSON, LINDA E.; 1345901, HUI, HO-WAH; 1345902, MILMAN, NELLY; 1345903, SEMLA, SUSAN J.)

Effective date: 20130830

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 16 YEARS UNTIL 06 MAR 2018 BY SPRUSON + FERGUSON

Effective date: 20140121

ASS Change of ownership

Owner name: BGP PRODUCTS OPERATIONS GMBH, CH

Effective date: 20160324

ERR Error or correction

Free format text: THE AGENT HAS BEEN CORRECTED TO 600753, SPRUSON + FERGUSON, PO BOX 30461, LOWER HUTT 5040, NZ; THE CONTACT HAS BEEN CORRECTED TO 600753, SPRUSON + FERGUSON, PO BOX 30461, LOWER HUTT 5040, NZ

Effective date: 20160526

EXPY Patent expired